Abstract
Schizophrenia is a common, debilitating mental illness that has persisted over the generations. For a disease with a strong genetic component, such prevalence has been difficult to understand in evolutionary terms. A model for its prevalence as a phenotype is presented in this manuscript, based on reports of specific differences in gene expression, metabolite levels and historical epidemiology. The selective force that underlies the proposed model is tuberculosis, a scourge of huge proportions that itself evolved to interact with the human host in a manner ensuring both its long term persistence in the host and its transfer to other carriers prior to the hosts unfortunate death. The focal point of the interaction between humans and M. tuberculosis is hypothesized to be the de novo synthesis of NAD via activation of the kynurenine pathway. The strategy that M. tuberculosis employed to circumvent this aspect of the hosts response to mycobacterial infection, and how that strategy interacted with a poor diet to force human evolution towards increased risk for schizophrenia, forms the basic premise of this paper. The model has implications for treatment of both diseases and generates hypotheses to be tested.
Keywords: Nicotinic acid, tuberculosis, schizophrenia, evolution
Current Pharmaceutical Design
Title: The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Volume: 15 Issue: 1
Author(s): Christine L. Miller
Affiliation:
Keywords: Nicotinic acid, tuberculosis, schizophrenia, evolution
Abstract: Schizophrenia is a common, debilitating mental illness that has persisted over the generations. For a disease with a strong genetic component, such prevalence has been difficult to understand in evolutionary terms. A model for its prevalence as a phenotype is presented in this manuscript, based on reports of specific differences in gene expression, metabolite levels and historical epidemiology. The selective force that underlies the proposed model is tuberculosis, a scourge of huge proportions that itself evolved to interact with the human host in a manner ensuring both its long term persistence in the host and its transfer to other carriers prior to the hosts unfortunate death. The focal point of the interaction between humans and M. tuberculosis is hypothesized to be the de novo synthesis of NAD via activation of the kynurenine pathway. The strategy that M. tuberculosis employed to circumvent this aspect of the hosts response to mycobacterial infection, and how that strategy interacted with a poor diet to force human evolution towards increased risk for schizophrenia, forms the basic premise of this paper. The model has implications for treatment of both diseases and generates hypotheses to be tested.
Export Options
About this article
Cite this article as:
Miller L. Christine, The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD, Current Pharmaceutical Design 2009; 15 (1) . https://dx.doi.org/10.2174/138161209787185805
DOI https://dx.doi.org/10.2174/138161209787185805 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glycosyltransferases, Important Tools for Drug Design
Current Topics in Medicinal Chemistry Recent Advances of Fluorescent Technologies for Drug Discovery and Development
Current Pharmaceutical Design Nasal Vaccines Against Hepatitis B: An Update
Current Pharmaceutical Biotechnology Current Understanding on Biosynthesis of Microbial Polysaccharides
Current Topics in Medicinal Chemistry An Integrated Drug Development Approach Applying Topological Descriptors
Current Computer-Aided Drug Design A Note on the Potential BCG Vaccination – COVID-19 Molecular Link
Coronaviruses TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Nanosuspensions of Poorly Water Soluble Drugs Prepared by Top-down Technologies
Current Pharmaceutical Design Persistent Clinical Response of Infliximab Therapy in Patients with Refractory Rheumatoid Arthritis, over a 3-Year Period
Current Clinical Pharmacology Ascorbic Acid: Its Role in Immune System and Chronic Inflammation Diseases
Mini-Reviews in Medicinal Chemistry Evaluation of Small Molecule Tuberculostats for Targeting Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Epidemiology of Gout: Perspectives from the Past
Current Rheumatology Reviews Second-Line Antiretroviral Therapy for HIV-Infected Children in Resource Limited Settings
Current Pediatric Reviews Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Utility of Non-Conventional Applications of Anti-VEGF Treatment in Selected Retinal Diseases
Current Drug Therapy Antimicrobial, Antitumor and Side Effects Assessment of a Newly Synthesized Tamoxifen Analog
Current Topics in Medicinal Chemistry New Lead Structures in Antifungal Drug Discovery
Current Medicinal Chemistry Strategically Placed Trifluoromethyl Substituent in the Realm of Antitubercular Drug Design
Current Drug Therapy Immunomodulatory Actions of Vitamin D Metabolites and their Potential Relevance to Human Lung Disease
Current Respiratory Medicine Reviews Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis
Current Rheumatology Reviews